福泰制药与德国达成协议 确保12岁及以上符合条件的患者获得Casgevy治疗

美股速递
May 06

福泰制药近日宣布与德国相关方面达成重要协议,将确保12岁及以上符合条件的患者能够获得其基因编辑疗法Casgevy。这一突破性安排标志着该创新疗法在德国市场的可及性取得重大进展。

根据协议条款,符合临床标准的青少年和成人患者将有机会接受这一变革性治疗。Casgevy作为基于CRISPR技术的基因编辑疗法,有望为特定遗传疾病患者提供新的治疗选择。

此次合作展现了福泰制药持续致力于扩大创新疗法的可及性,同时也反映了德国医疗体系对前沿医疗技术的接纳与支持。该协议的落实将为符合条件的患者群体带来新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10